Amanta Healthcare Limited is a leading pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of sterile liquid products, including parenteral products packaged using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. The company manufactures both large volume parenterals (LVPs) and small volume parenterals (SVPs) across six therapeutic segments, and also produces medical devices, catering to domestic and international markets.

The Amanta Healthcare IPO is a Book Built Issue amounting to ₹126 Crores, consisting entirely of a fresh issue of 10 lakh shares. The subscription period opened on 1 September 2025 and closed on 3 September 2025, with allotment expected on 4 September 2025, and a tentative listing on BSE & NSE on 9 September 2025. The price band was set at ₹120 to ₹126 per share, with a lot size of 119 shares. Retail investors were required to invest a minimum of ₹14,994 (119 shares), while High-Net-Worth Individuals (HNIs) needed a minimum of ₹2,09,916 (14 lots / 1,666 shares).

The IPO was managed by BEELINE CAPITAL ADVISORS PRIVATE LIMITED as the Book Running Lead Manager, with MUFG INTIME INDIA PRIVATE LIMITED as the registrar. The Grey Market Premium (GMP) is ₹14, indicating strong expected listing gains. The IPO was subscribed 11.39 times on its final day of subscription, reflecting high investor demand. Additionally, Anchor Investors subscribed for ₹37.8 Crores at the upper band price of ₹126 per share.

IPO Objectives:
The company intends to utilize the net proceeds as follows:

1. ₹70 crore for funding capital expenditure, civil construction, and purchase of equipment, plant, and machinery for the new SteriPort manufacturing line at Hariyala, Kheda, Gujarat.

2. ₹30.13 crore for setting up a new SVP manufacturing line, including civil construction and machinery costs.

3. General corporate purposes, supporting strategic business initiatives and operational growth.

Management and Leadership:
The company is led by Bhavesh Patel, Promoter, Chairman, and Managing Director, who has approximately 30 years of experience in pharmaceutical manufacturing and marketing. The senior management team also possesses diverse experience and qualifications in accounts, science, and pharmacy, providing strong strategic and operational guidance.

Financial Performance:
Amanta Healthcare has demonstrated steady revenue growth with significant EBITDA expansion:

• Revenue: ₹27,609.34 Lakh (FY25), ₹28,160.68 Lakh (FY24), ₹26,269.62 Lakh (FY23)

• EBITDA: ₹13,569.13 Lakh (FY25), ₹12,313.42 Lakh (FY24), ₹10,731.76 Lakh (FY23)

• Profit After Tax (PAT): ₹1,050.07 Lakh (FY25), ₹363.32 Lakh (FY24), ₹-211.06 Lakh (FY23)

Key metrics include pre-issue EPS of ₹3.71, post-issue EPS of ₹2.70, pre-issue P/E ratio of 33.96x, post-issue P/E ratio of 46.59x, ROCE at 13.72%, and ROE at 12.42%. Compared to the industry P/E ratio of 16x, the IPO is fully priced.

IPO Listing Outlook:
With a Grey Market Premium of ₹14, investors can expect potential listing gains of 11.11%. Given the company’s financial performance and the valuation, the IPO may appeal to risk-tolerant investors seeking exposure to the pharmaceutical sterile liquid and medical device sector.

The IPO proceeds will strengthen the company’s manufacturing capabilities, enable expansion into new product lines, and support overall business growth, positioning Amanta Healthcare for continued success in the pharmaceutical sector.

The Upcoming IPOs in this week and coming weeks are Taurian MPS, Jay Ambe Supermarkets, Krupalu Metals, Urban Company, Shringar House of Mangalsutra, Vashishtha Luxury Fashion, Karbonsteel Engineering, Sharvaya Metals, Vigor Plast India.

The Current active IPO are Austere Systems, Optivalue Tek Consulting, Goel Construction Company, Amanta Healthcare, Rachit Prints.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.